By Scott Buzby
In patients with end-stage HF awaiting transplant, catheter ablation for atrial fibrillation was safe and effective and was associated with improvements in left ventricular ejection fraction and AF burden, a speaker reported.
The duration of follow-up was intended to be 3 years, but due to the number of clinical events, the trial data safety monitoring board recommended to stop the study prematurely at 1.5 years. Read the full story in Healio.